Discovering and developing innovative therapeutics for CNS disorders

Welcome to the Newron Pharmaceuticals website.
We are a clinical-stage biopharmaceutical company. Our shares are listed on the SWX Swiss Exchange (NWRN). Our mission is to discover, develop and commercialise novel drugs to treat diseases of the Central Nervous System (CNS) and pain.

Latest Press Releases

Newron announces completion of patient enrollment in phase III clinical trial of safinamide in mid- to late-stage Parkinson’s Disease

22/05/2008
English ENG  German GER

Newron closes acquisition of Hunter-Fleming

14/05/2008
English ENG  German GER

Investor News

Please click here to view Newron share price information on SWX.

take a tour of the brainjobs at newron